Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brigimadlin in dedifferentiated liposarcoma
NCT06058793Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, open-label trial of brigimadlin in dedifferentiated liposarcoma (DDL) (2 cohorts), sponsored by Boehringer Ingelheim. Primary endpoints: Treatment-emergent Adverse Events at 23 months and Grade ≥3 Treatment-emergent Adverse Events at 23 months. Started Dec 2023; status: completed.
02
Drugs
brigimadlin
03
Conditions
dedifferentiated liposarcoma (DDL)
Beyond the preview
Go deeper on NCT06058793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06058793.